drugset / Trial / NCT00093886

Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)

NCT00093886

Phase 3 Completed 629 enrolled The Medicines Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to establish the safety of clevidipine in the treatment of perioperative hypertension. Approximately 500-900 patients with perioperative hypertension undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or valve replacement/repair procedures were anticipated to be randomly assigned to one of two treatment groups: clevidipine or nitroglycerin.

Timeline

Start
2004-04
Primary completion
2005-03
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Clevidipine Small molecule Intravenous
Comparator Nitroglycerin Unknown Intravenous

Indications